comprehensive -WSS

comprehensive

author：entertainment 2025-10-02 23:59:54 - browse：3421

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Trump surgeon general acknowledges mistakes during Covid

WSS

NYU radiologists take on the challenge of expensive MRI machines

David Sabatini, ex

'Make People Better': The CRISPR babies story you probably don't know

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Humana sues Biden admin over Medicare Advantage audit rule

focus

comprehensive

hotspot

Apple is now the first public company to be valued at $3 trillion

A rare thyroid diagnosis led to unexpected, all

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Amazon on where the company's health care bets are headed next

Supreme Court strikes down use of affirmative action

Ethical issues complicate the benefits of medical crowdfunding

Virginia high school admissions case could be legal follow

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Peter Hotez and the public health issue of online harassment

Anthos stroke drug appears safer than common blood thinner

leisure time

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Medicaid rebukes states for mistakenly disenrolling children

What American doctors can learn from their Israeli counterparts

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

David Sabatini, ex

Hospitals look to new technology to keep health care workers safe

focus

focus

explore

hotspot